Point of Care Diagnostics Market by Product (Glucose, Infectious Disease [TB, HAI, STD], Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx [RT-PCR, INAAT]), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2031
The Point of Care Diagnostics market is projected to reach USD 31.46 billion by 2031 from USD 20.63 billion in 2026, growing at a CAGR of 8.8%.
Continuous technological advancements and the growing demand for rapid, accurate, and decentralized testing are driving growth in the point-of-care diagnostics market. Biochemistry technology accounts for the largest market share due to its widespread use in blood glucose monitoring, blood gas and electrolyte analysis, cholesterol testing, and other routine diagnostic applications across hospitals, clinical laboratories, emergency departments, and physician offices. Its broad clinical utility, cost-effectiveness, and ability to deliver rapid results make it the preferred technology for high-volume point-of-care testing. Meanwhile, molecular diagnostics is projected to grow the fastest, owing to the increasing adoption of rapid PCR-based platforms for infectious disease detection, antimicrobial resistance testing, and outbreak preparedness. Continuous innovations in immunoassays, molecular platforms, microfluidics, multiplex testing, and portable analyzers are improving diagnostic accuracy, reducing turnaround time, and expanding testing beyond traditional laboratories. These advancements are accelerating the adoption of next-generation point-of-care diagnostic technologies across hospitals, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings, thereby creating sustained global demand for advanced diagnostic solutions.
Based on product: Infectious disease testing products are projected to register the highest growth during the forecast period. The segment's dominance is driven by the increasing burden of infectious diseases, the growing demand for rapid, accurate near-patient diagnosis, and the need for timely clinical decision-making to support effective treatment and infection control. The growing adoption of point-of-care testing across hospitals, emergency departments, physicians' offices, retail clinics, pharmacies, and home healthcare settings, coupled with expanding government initiatives for infectious disease surveillance and decentralized healthcare delivery, continues to strengthen the market position of infectious disease testing products.
Based on end user: Clinical laboratories account for the largest share of the point-of-care diagnostics market due to their central role in delivering rapid and accurate diagnostic testing for both acute and chronic diseases. These facilities routinely perform point-of-care testing for infectious diseases, diabetes, cardiovascular disorders, coagulation monitoring, and clinical chemistry, supporting timely diagnosis and treatment decisions. Their extensive testing capabilities, skilled laboratory personnel, established quality management systems, and seamless integration with hospital workflows continue to drive demand for point-of-care diagnostic solutions. Furthermore, increasing test volumes, the growing emphasis on faster turnaround times, and the expanding adoption of decentralized testing within laboratory networks reinforce the dominance of clinical laboratories in the global point-of-care diagnostics market.
North America accounts for the largest share of the point-of-care diagnostics market due to its advanced healthcare infrastructure, strong reimbursement framework, and widespread adoption of decentralized diagnostic testing. The region has an extensive network of hospitals, clinical laboratories, physicians' offices, urgent care centers, retail clinics, and pharmacies that routinely use point-of-care diagnostics to rapidly detect and manage infectious diseases, diabetes, cardiovascular disorders, and respiratory conditions. High healthcare expenditure, a strong presence of leading diagnostic manufacturers, and favorable regulatory support have accelerated the adoption of point-of-care testing across the U.S. and Canada. Furthermore, increasing emphasis on early diagnosis, improved patient outcomes, and reducing healthcare costs through near-patient testing continues to reinforce North America's leadership in the global point-of-care diagnostics market.
A breakdown of the primary respondents (supply-side) for the POC diagnostics s market referred to in this report is provided below:
Research Coverage
The report evaluates the POC diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will assist market leaders and new entrants in the POC diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the POC diagnostics market.
This report provides insights into the following points:
Continuous technological advancements and the growing demand for rapid, accurate, and decentralized testing are driving growth in the point-of-care diagnostics market. Biochemistry technology accounts for the largest market share due to its widespread use in blood glucose monitoring, blood gas and electrolyte analysis, cholesterol testing, and other routine diagnostic applications across hospitals, clinical laboratories, emergency departments, and physician offices. Its broad clinical utility, cost-effectiveness, and ability to deliver rapid results make it the preferred technology for high-volume point-of-care testing. Meanwhile, molecular diagnostics is projected to grow the fastest, owing to the increasing adoption of rapid PCR-based platforms for infectious disease detection, antimicrobial resistance testing, and outbreak preparedness. Continuous innovations in immunoassays, molecular platforms, microfluidics, multiplex testing, and portable analyzers are improving diagnostic accuracy, reducing turnaround time, and expanding testing beyond traditional laboratories. These advancements are accelerating the adoption of next-generation point-of-care diagnostic technologies across hospitals, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings, thereby creating sustained global demand for advanced diagnostic solutions.
Based on product: Infectious disease testing products are projected to register the highest growth during the forecast period. The segment's dominance is driven by the increasing burden of infectious diseases, the growing demand for rapid, accurate near-patient diagnosis, and the need for timely clinical decision-making to support effective treatment and infection control. The growing adoption of point-of-care testing across hospitals, emergency departments, physicians' offices, retail clinics, pharmacies, and home healthcare settings, coupled with expanding government initiatives for infectious disease surveillance and decentralized healthcare delivery, continues to strengthen the market position of infectious disease testing products.
Based on end user: Clinical laboratories account for the largest share of the point-of-care diagnostics market due to their central role in delivering rapid and accurate diagnostic testing for both acute and chronic diseases. These facilities routinely perform point-of-care testing for infectious diseases, diabetes, cardiovascular disorders, coagulation monitoring, and clinical chemistry, supporting timely diagnosis and treatment decisions. Their extensive testing capabilities, skilled laboratory personnel, established quality management systems, and seamless integration with hospital workflows continue to drive demand for point-of-care diagnostic solutions. Furthermore, increasing test volumes, the growing emphasis on faster turnaround times, and the expanding adoption of decentralized testing within laboratory networks reinforce the dominance of clinical laboratories in the global point-of-care diagnostics market.
North America accounts for the largest share of the point-of-care diagnostics market due to its advanced healthcare infrastructure, strong reimbursement framework, and widespread adoption of decentralized diagnostic testing. The region has an extensive network of hospitals, clinical laboratories, physicians' offices, urgent care centers, retail clinics, and pharmacies that routinely use point-of-care diagnostics to rapidly detect and manage infectious diseases, diabetes, cardiovascular disorders, and respiratory conditions. High healthcare expenditure, a strong presence of leading diagnostic manufacturers, and favorable regulatory support have accelerated the adoption of point-of-care testing across the U.S. and Canada. Furthermore, increasing emphasis on early diagnosis, improved patient outcomes, and reducing healthcare costs through near-patient testing continues to reinforce North America's leadership in the global point-of-care diagnostics market.
A breakdown of the primary respondents (supply-side) for the POC diagnostics s market referred to in this report is provided below:
- By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
- By Designation: C-level: 55%, Director Level: 27%, and Others: 18%
- By Region: North America: 43%, Europe: 28%, Asia Pacific: 20%, Latin America: 6%, and Middle East & Africa: 3%
Research Coverage
The report evaluates the POC diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will assist market leaders and new entrants in the POC diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the POC diagnostics market.
This report provides insights into the following points:
- Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases requiring rapid diagnosis, growing demand for decentralized and near-patient testing to enable faster clinical decision-making, increasing adoption of portable and user-friendly diagnostic devices in hospitals, clinics, and home care settings, technological advancements in microfluidics, biosensors, AI-enabled diagnostics, and smartphone-integrated testing solutions), restraints (high cost of advanced point-of-care diagnostic devices and consumables, stringent regulatory approval and quality compliance requirements, limited accuracy of certain rapid tests compared to centralized laboratory testing, data security and interoperability concerns with connected diagnostic systems), opportunities (expansion of point-of-care testing in emerging markets, increasing demand for home-based diagnostic kits and self-testing solutions, growing adoption of multiplex and molecular point-of-care diagnostics, rising investments in digital health, telemedicine, and AI-powered diagnostic platforms), and challenges (limited healthcare infrastructure and trained personnel in low-resource settings, reimbursement and pricing pressures, supply chain constraints for diagnostic reagents and consumables, standardization and integration of point-of-care diagnostic data with electronic health record systems)
- Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global POC diagnostics market.
- Market Development: Thorough knowledge and analysis of the profitable rising markets by product, sample, mode of purchase, technology, end user, and region.
- Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global POC diagnostics market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global POC diagnostics market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 POC DIAGNOSTICS MARKET OVERVIEW
3.2 POC DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031
3.3 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2026 VS. 2031
3.4 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.5 POC DIAGNOSTICS MARKET, BY SAMPLE, 2026 VS. 2031
3.6 POC DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031
3.7 POC DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing incidence of infectious diseases
4.2.1.2 Increasing prevalence of chronic diseases
4.2.1.3 Favorable government initiatives for POC testing
4.2.1.4 Rising number of waived tests
4.2.2 RESTRAINTS
4.2.2.1 Pricing pressure on manufacturers
4.2.2.2 Stringent regulatory approval process for product commercialization
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing growth potential in emerging markets
4.2.3.2 Rising inclination toward decentralized healthcare systems
4.2.3.3 Booming healthcare spending worldwide
4.2.4 CHALLENGES
4.2.4.1 Inadequate standardization with centralized lab methods
4.2.4.2 Premium pricing of novel platforms
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN POC DIAGNOSTICS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 INVESTMENT AND FUNDING SCENARIO
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE, BY PRODUCT
5.6.1.1 Average selling price OF glucose monitoring test strips, by key player
5.6.2 AVERAGE SELLING PRICE, BY REGION
5.6.2.1 Average selling price of glucose monitoring test strips, by region
5.6.2.2 Average selling price of infectious disease testing products, by region
5.6.2.3 Average selling price of cardiometabolic monitoring products, by region
5.7 VALUE CHAIN ANALYSIS
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 IMPACT OF US TARIFFS—POC DIAGNOSTICS MARKET
5.9.1 INTRODUCTION
5.9.2 KEY TARIFF RATES
5.9.3 PRICE IMPACT ANALYSIS
5.9.4 IMPACT ON COUNTRIES/REGIONS
5.9.4.1 North America
5.9.4.2 Europe
5.9.4.3 Asia Pacific
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 IMMUNOASSAYS
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 MOLECULAR DIAGNOSTICS
6.3 ADJACENT TECHNOLOGIES
6.3.1 BIOCHEMICAL TECHNOLOGIES
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 LIST OF MAJOR PATENTS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON POC DIAGNOSTICS MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES AND MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN POC DIAGNOSTICS
7.2.1.1 Eco-friendly Initiatives
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 BIOCHEMISTRY
9.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
9.3 IMMUNOASSAYS
9.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
9.4 MOLECULAR DIAGNOSTICS
9.4.1 RT-PCR
9.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market
9.4.2 INAAT
9.4.2.1 Emerging new pathogens to facilitate growth
10 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE
10.1 INTRODUCTION
10.2 BLOOD SAMPLES
10.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
10.3 NASAL & OROPHARYNGEAL SWABS
10.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
10.4 URINE SAMPLES
10.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
10.5 OTHER SAMPLES
11 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
11.1 INTRODUCTION
11.2 PRESCRIPTION-BASED TESTING PRODUCTS
11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
11.3 OTC TESTING PRODUCTS
11.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
12 POINT OF CARE DIAGNOSTICS MARKET, BY END USER
12.1 INTRODUCTION
12.2 CLINICAL LABORATORIES
12.2.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
12.3 HOME CARE SETTINGS & SELF-TESTING
12.3.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
12.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
12.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
12.5 AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES
12.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
12.6 OTHER END USERS
13 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
13.1 INTRODUCTION
13.2 GLUCOSE MONITORING PRODUCTS
13.2.1 GLUCOSE MONITORING STRIPS
13.2.1.1 Growing trend toward preventive healthcare to drive market
13.2.2 GLUCOSE MONITORING METERS
13.2.2.1 Growing technological advancements in glucose meters to propel market
13.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES
13.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth
13.3 CARDIOMETABOLIC TESTING PRODUCTS
13.3.1 CARDIAC MARKER TESTING PRODUCTS
13.3.1.1 Growing government support for cardiovascular diseases to drive market
13.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
13.3.2.1 Need to optimize hospital workflow to favor growth
13.3.3 HBA1C TESTING PRODUCTS
13.3.3.1 Increasing recommendations by government healthcare authorities to boost market
13.4 INFECTIOUS DISEASE TESTING PRODUCTS
13.4.1 RESPIRATORY INFECTION TESTING PRODUCTS
13.4.1.1 Influenza testing products
13.4.1.1.1 Need for targeted treatments to expedite growth
13.4.1.2 Tuberculosis testing products
13.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth
13.4.1.3 Other respiratory infection testing products
13.4.2 HAI TESTING PRODUCTS
13.4.2.1 Growing rate of surgical-site infections to boost market
13.4.3 TROPICAL DISEASE TESTING PRODUCTS
13.4.3.1 Rising incidence of malaria and dengue to support growth
13.4.4 STD TESTING PRODUCTS
13.4.4.1 HIV testing products
13.4.4.1.1 Growing availability and awareness of testing products to boost market
13.4.4.2 Hepatitis testing products
13.4.4.2.1 Hepatitis B testing products
13.4.4.2.1.1 Increasing prevalence of liver infections to favor growth
13.4.4.2.2 Hepatitis C testing products
13.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth
13.4.4.3 Syphilis testing products
13.4.4.3.1 Need for early and accessible diagnosis to expedite growth
13.4.4.4 Human papillomavirus testing products
13.4.4.4.1 Rising cases of cervical cancer to promote growth
13.4.4.5 Chlamydia trachomatis testing products
13.4.4.5.1 Growing adoption of advanced techniques to drive market
13.4.4.6 Neisseria gonorrhea testing products
13.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
13.4.4.7 HSV testing products
13.4.4.7.1 Increasing incidence of herpes to support growth
13.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
13.4.5.1 Rising cases among hospitalized patients to boost demand
13.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
13.5 COAGULATION MONITORING PRODUCTS
13.5.1 NEED FOR REGULAR MONITORING AND RISING DEMAND FOR HOME-USE KITS TO PROPEL MARKET
13.5.2 PT/INR TESTING PRODUCTS
13.5.2.1 Increasing number of atrial fibrillation cases to accelerate growth
13.5.3 ACT/APTT TESTING PRODUCTS
13.5.3.1 Rise in surgical procedures to speed up growth
13.6 PREGNANCY & FERTILITY TESTING PRODUCTS
13.6.1 PREGNANCY TESTING PRODUCTS
13.6.1.1 Increasing awareness about family planning to stimulate growth
13.6.2 FERTILITY TESTING PRODUCTS
13.6.2.1 Growing infertility issues to fuel market
13.7 TUMOR/CANCER MARKER TESTING PRODUCTS
13.7.1 GROWING CANCER INCIDENCE AND GOVERNMENT SUPPORT FOR CANCER MANAGEMENT AND THERAPIES DRIVE MARKET
13.8 URINALYSIS TESTING PRODUCTS
13.8.1 INCREASING DEMAND FOR RAPID POC TESTING TECHNOLOGIES TO SUPPORT MARKET GROWTH
13.9 CHOLESTEROL TESTING PRODUCTS
13.9.1 GROWING GERIATRIC POPULATION AND RISING OBESITY LEVELS TO DRIVE MARKET
13.10 HEMATOLOGY TESTING PRODUCTS
13.10.1 RAPID DIAGNOSTICS AND MONITORING SUPPORT TO PROPEL END-USER ADOPTION
13.11 DRUGS-OF-ABUSE TESTING PRODUCTS
13.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
13.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
13.12.1 GROWING PREVALENCE OF THYROID DISORDERS DRIVING DEMAND FOR TSH TESTING PRODUCTS
13.13 FECAL OCCULT TESTING PRODUCTS
13.13.1 GROWING INCIDENCE OF CANCER TO PROPEL THE MARKET
13.14 OTHER PRODUCTS
14 POINT OF CARE DIAGNOSTICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 US
14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditure to aid growth
14.2.3 CANADA
14.2.3.1 Rising incidence of diabetes and infectious diseases to support growth
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2 GERMANY
14.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth
14.3.3 FRANCE
14.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market
14.3.4 UK
14.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth
14.3.5 ITALY
14.3.5.1 Growing burden of infectious and parasitic diseases to boost market
14.3.6 SPAIN
14.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth
14.3.7 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 CHINA
14.4.2.1 Increasing impact of diabetes on public health to amplify growth
14.4.3 JAPAN
14.4.3.1 Booming geriatric population to stimulate growth
14.4.4 INDIA
14.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth
14.4.5 AUSTRALIA
14.4.5.1 Growing research investments for next-gen POC devices to boost market
14.4.6 SOUTH KOREA
14.4.6.1 Growing focus on innovative diagnostic products to drive market
14.4.7 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 BRAZIL
14.5.2.1 Increasing public initiatives in healthcare to encourage growth
14.5.3 MEXICO
14.5.3.1 Need for frequent testing for disease management to expedite growth
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POC DIAGNOSTICS MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY VALUATION AND FINANCIAL METRICS
15.6 BRAND/PRODUCT COMPARISON
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.7.1 STARS
15.7.2 EMERGING LEADERS
15.7.3 PERVASIVE PLAYERS
15.7.4 PARTICIPANTS
15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025
15.7.5.1 Company footprint
15.7.5.2 Region footprint
15.7.5.3 Mode of purchase footprint
15.7.5.4 Technology footprint
15.7.5.5 Sample footprint
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
15.8.1 PROGRESSIVE COMPANIES
15.8.2 RESPONSIVE COMPANIES
15.8.3 DYNAMIC COMPANIES
15.8.4 STARTING BLOCKS
15.8.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
15.8.5.1 Detailed list of key startups/SMEs
15.8.5.2 Competitive benchmarking of startups/SMEs
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES AND APPROVALS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 ABBOTT
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches and approvals
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 F. HOFFMANN-LA ROCHE LTD
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches and approvals
16.1.2.3.2 Deals
16.1.2.3.3 Expansions
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 SIEMENS HEALTHINEERS AG
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches and approvals
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 QUIDELORTHO CORPORATION
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product launches and approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 DANAHER
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches and approvals
16.1.5.3.2 Deals
16.1.5.3.3 Expansions
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 WERFEN
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches and approvals
16.1.6.3.2 Deals
16.1.6.3.3 Expansions
16.1.6.4 MnM view
16.1.6.4.1 Right to win
16.1.6.4.2 Strategic choices
16.1.6.4.3 Weaknesses and competitive threats
16.1.7 BD
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches and approvals
16.1.7.3.2 Deals
16.1.7.3.3 Expansions
16.1.8 THERMO FISHER SCIENTIFIC INC.
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.9 BIOM?RIEUX
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches and approvals
16.1.9.3.2 Deals
16.1.10 EKF DIAGNOSTICS HOLDINGS PLC
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches and approvals
16.1.10.3.2 Expansions
16.1.10.3.3 Other developments
16.1.11 TRINITY BIOTECH
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches and approvals
16.1.11.3.2 Deals
16.1.12 ORASURE TECHNOLOGIES, INC.
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches and approvals
16.1.12.3.2 Deals
16.1.13 GRIFOLS S.A.
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Product launches and approvals
16.1.14 QIAGEN
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches and approvals
16.1.14.3.2 Deals
16.1.14.3.3 Expansions
16.2 OTHER PLAYERS
16.2.1 NOVA BIOMEDICAL
16.2.1.1 Business overview
16.2.1.2 Products offered
16.2.1.3 Recent developments
16.2.1.3.1 Product launches and approvals
16.2.1.3.2 Deals
16.2.2 SEKISUI DIAGNOSTICS
16.2.2.1 Business overview
16.2.2.2 Products offered
16.2.2.3 Recent developments
16.2.2.3.1 Product launches and approvals
16.2.3 SEKISUI DIAGNOSTICS
16.2.3.1 Business overview
16.2.3.2 Products offered
16.2.3.3 Recent developments
16.2.3.3.1 Product launches and approvals
16.2.4 LIFESCAN IP HOLDINGS, LLC
16.2.5 PTS DIAGNOSTICS
16.2.6 EUROLYSER DIAGNOSTICA GMBH
16.2.7 RESPONSE BIOMEDICAL
16.2.8 ALFA SCIENTIFIC DESIGNS, INC.
16.2.9 BTNX INC.
16.2.10 ASCENSIA DIABETES CARE HOLDINGS AG
16.2.11 FLUXERGY
16.2.12 PRECISION BIOSENSOR, INC.
16.2.13 ACON LABORATORIES, INC.
16.2.14 MENARINI DIAGNOSTICS S.R.L
16.2.15 MANKIND PHARMA
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.2 RESEARCH APPROACH
17.2.1 SECONDARY RESEARCH
17.2.1.1 Key data from secondary sources
17.2.2 PRIMARY DATA
17.2.2.1 Primary sources
17.2.2.2 Key data from primary sources
17.2.2.3 Key industry insights
17.3 MARKET SIZE ESTIMATION
17.3.1 BOTTOM-UP APPROACH
17.3.1.1 Approach 1: Company revenue estimation approach
17.3.1.2 Approach 2: Presentations of companies and primary interviews
17.3.1.3 Growth forecast
17.3.2 TOP-DOWN APPROACH
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 MARKET SHARE ANALYSIS
17.6 RESEARCH ASSUMPTIONS
17.6.1 PARAMETRIC ASSUMPTIONS
17.6.2 GROWTH RATE ASSUMPTIONS
17.7 RESEARCH LIMITATIONS
17.8 RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 POC DIAGNOSTICS MARKET OVERVIEW
3.2 POC DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031
3.3 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2026 VS. 2031
3.4 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.5 POC DIAGNOSTICS MARKET, BY SAMPLE, 2026 VS. 2031
3.6 POC DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031
3.7 POC DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing incidence of infectious diseases
4.2.1.2 Increasing prevalence of chronic diseases
4.2.1.3 Favorable government initiatives for POC testing
4.2.1.4 Rising number of waived tests
4.2.2 RESTRAINTS
4.2.2.1 Pricing pressure on manufacturers
4.2.2.2 Stringent regulatory approval process for product commercialization
4.2.3 OPPORTUNITIES
4.2.3.1 Increasing growth potential in emerging markets
4.2.3.2 Rising inclination toward decentralized healthcare systems
4.2.3.3 Booming healthcare spending worldwide
4.2.4 CHALLENGES
4.2.4.1 Inadequate standardization with centralized lab methods
4.2.4.2 Premium pricing of novel platforms
4.3 UNMET NEEDS AND WHITE SPACES
4.3.1 UNMET NEEDS IN POC DIAGNOSTICS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES AND STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.3 SUPPLY CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.5 INVESTMENT AND FUNDING SCENARIO
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE, BY PRODUCT
5.6.1.1 Average selling price OF glucose monitoring test strips, by key player
5.6.2 AVERAGE SELLING PRICE, BY REGION
5.6.2.1 Average selling price of glucose monitoring test strips, by region
5.6.2.2 Average selling price of infectious disease testing products, by region
5.6.2.3 Average selling price of cardiometabolic monitoring products, by region
5.7 VALUE CHAIN ANALYSIS
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 IMPACT OF US TARIFFS—POC DIAGNOSTICS MARKET
5.9.1 INTRODUCTION
5.9.2 KEY TARIFF RATES
5.9.3 PRICE IMPACT ANALYSIS
5.9.4 IMPACT ON COUNTRIES/REGIONS
5.9.4.1 North America
5.9.4.2 Europe
5.9.4.3 Asia Pacific
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 IMMUNOASSAYS
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 MOLECULAR DIAGNOSTICS
6.3 ADJACENT TECHNOLOGIES
6.3.1 BIOCHEMICAL TECHNOLOGIES
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 LIST OF MAJOR PATENTS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON POC DIAGNOSTICS MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES AND MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN POC DIAGNOSTICS
7.2.1.1 Eco-friendly Initiatives
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 BIOCHEMISTRY
9.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
9.3 IMMUNOASSAYS
9.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
9.4 MOLECULAR DIAGNOSTICS
9.4.1 RT-PCR
9.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market
9.4.2 INAAT
9.4.2.1 Emerging new pathogens to facilitate growth
10 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE
10.1 INTRODUCTION
10.2 BLOOD SAMPLES
10.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
10.3 NASAL & OROPHARYNGEAL SWABS
10.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
10.4 URINE SAMPLES
10.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
10.5 OTHER SAMPLES
11 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
11.1 INTRODUCTION
11.2 PRESCRIPTION-BASED TESTING PRODUCTS
11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
11.3 OTC TESTING PRODUCTS
11.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
12 POINT OF CARE DIAGNOSTICS MARKET, BY END USER
12.1 INTRODUCTION
12.2 CLINICAL LABORATORIES
12.2.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
12.3 HOME CARE SETTINGS & SELF-TESTING
12.3.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
12.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
12.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
12.5 AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES
12.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
12.6 OTHER END USERS
13 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
13.1 INTRODUCTION
13.2 GLUCOSE MONITORING PRODUCTS
13.2.1 GLUCOSE MONITORING STRIPS
13.2.1.1 Growing trend toward preventive healthcare to drive market
13.2.2 GLUCOSE MONITORING METERS
13.2.2.1 Growing technological advancements in glucose meters to propel market
13.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES
13.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth
13.3 CARDIOMETABOLIC TESTING PRODUCTS
13.3.1 CARDIAC MARKER TESTING PRODUCTS
13.3.1.1 Growing government support for cardiovascular diseases to drive market
13.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
13.3.2.1 Need to optimize hospital workflow to favor growth
13.3.3 HBA1C TESTING PRODUCTS
13.3.3.1 Increasing recommendations by government healthcare authorities to boost market
13.4 INFECTIOUS DISEASE TESTING PRODUCTS
13.4.1 RESPIRATORY INFECTION TESTING PRODUCTS
13.4.1.1 Influenza testing products
13.4.1.1.1 Need for targeted treatments to expedite growth
13.4.1.2 Tuberculosis testing products
13.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth
13.4.1.3 Other respiratory infection testing products
13.4.2 HAI TESTING PRODUCTS
13.4.2.1 Growing rate of surgical-site infections to boost market
13.4.3 TROPICAL DISEASE TESTING PRODUCTS
13.4.3.1 Rising incidence of malaria and dengue to support growth
13.4.4 STD TESTING PRODUCTS
13.4.4.1 HIV testing products
13.4.4.1.1 Growing availability and awareness of testing products to boost market
13.4.4.2 Hepatitis testing products
13.4.4.2.1 Hepatitis B testing products
13.4.4.2.1.1 Increasing prevalence of liver infections to favor growth
13.4.4.2.2 Hepatitis C testing products
13.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth
13.4.4.3 Syphilis testing products
13.4.4.3.1 Need for early and accessible diagnosis to expedite growth
13.4.4.4 Human papillomavirus testing products
13.4.4.4.1 Rising cases of cervical cancer to promote growth
13.4.4.5 Chlamydia trachomatis testing products
13.4.4.5.1 Growing adoption of advanced techniques to drive market
13.4.4.6 Neisseria gonorrhea testing products
13.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
13.4.4.7 HSV testing products
13.4.4.7.1 Increasing incidence of herpes to support growth
13.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
13.4.5.1 Rising cases among hospitalized patients to boost demand
13.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
13.5 COAGULATION MONITORING PRODUCTS
13.5.1 NEED FOR REGULAR MONITORING AND RISING DEMAND FOR HOME-USE KITS TO PROPEL MARKET
13.5.2 PT/INR TESTING PRODUCTS
13.5.2.1 Increasing number of atrial fibrillation cases to accelerate growth
13.5.3 ACT/APTT TESTING PRODUCTS
13.5.3.1 Rise in surgical procedures to speed up growth
13.6 PREGNANCY & FERTILITY TESTING PRODUCTS
13.6.1 PREGNANCY TESTING PRODUCTS
13.6.1.1 Increasing awareness about family planning to stimulate growth
13.6.2 FERTILITY TESTING PRODUCTS
13.6.2.1 Growing infertility issues to fuel market
13.7 TUMOR/CANCER MARKER TESTING PRODUCTS
13.7.1 GROWING CANCER INCIDENCE AND GOVERNMENT SUPPORT FOR CANCER MANAGEMENT AND THERAPIES DRIVE MARKET
13.8 URINALYSIS TESTING PRODUCTS
13.8.1 INCREASING DEMAND FOR RAPID POC TESTING TECHNOLOGIES TO SUPPORT MARKET GROWTH
13.9 CHOLESTEROL TESTING PRODUCTS
13.9.1 GROWING GERIATRIC POPULATION AND RISING OBESITY LEVELS TO DRIVE MARKET
13.10 HEMATOLOGY TESTING PRODUCTS
13.10.1 RAPID DIAGNOSTICS AND MONITORING SUPPORT TO PROPEL END-USER ADOPTION
13.11 DRUGS-OF-ABUSE TESTING PRODUCTS
13.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
13.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
13.12.1 GROWING PREVALENCE OF THYROID DISORDERS DRIVING DEMAND FOR TSH TESTING PRODUCTS
13.13 FECAL OCCULT TESTING PRODUCTS
13.13.1 GROWING INCIDENCE OF CANCER TO PROPEL THE MARKET
13.14 OTHER PRODUCTS
14 POINT OF CARE DIAGNOSTICS MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2 US
14.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditure to aid growth
14.2.3 CANADA
14.2.3.1 Rising incidence of diabetes and infectious diseases to support growth
14.3 EUROPE
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
14.3.2 GERMANY
14.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth
14.3.3 FRANCE
14.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market
14.3.4 UK
14.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth
14.3.5 ITALY
14.3.5.1 Growing burden of infectious and parasitic diseases to boost market
14.3.6 SPAIN
14.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth
14.3.7 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2 CHINA
14.4.2.1 Increasing impact of diabetes on public health to amplify growth
14.4.3 JAPAN
14.4.3.1 Booming geriatric population to stimulate growth
14.4.4 INDIA
14.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth
14.4.5 AUSTRALIA
14.4.5.1 Growing research investments for next-gen POC devices to boost market
14.4.6 SOUTH KOREA
14.4.6.1 Growing focus on innovative diagnostic products to drive market
14.4.7 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.2 BRAZIL
14.5.2.1 Increasing public initiatives in healthcare to encourage growth
14.5.3 MEXICO
14.5.3.1 Need for frequent testing for disease management to expedite growth
14.5.4 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POC DIAGNOSTICS MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY VALUATION AND FINANCIAL METRICS
15.6 BRAND/PRODUCT COMPARISON
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.7.1 STARS
15.7.2 EMERGING LEADERS
15.7.3 PERVASIVE PLAYERS
15.7.4 PARTICIPANTS
15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025
15.7.5.1 Company footprint
15.7.5.2 Region footprint
15.7.5.3 Mode of purchase footprint
15.7.5.4 Technology footprint
15.7.5.5 Sample footprint
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
15.8.1 PROGRESSIVE COMPANIES
15.8.2 RESPONSIVE COMPANIES
15.8.3 DYNAMIC COMPANIES
15.8.4 STARTING BLOCKS
15.8.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
15.8.5.1 Detailed list of key startups/SMEs
15.8.5.2 Competitive benchmarking of startups/SMEs
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES AND APPROVALS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 ABBOTT
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches and approvals
16.1.1.3.2 Deals
16.1.1.4 MnM view
16.1.1.4.1 Right to win
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses and competitive threats
16.1.2 F. HOFFMANN-LA ROCHE LTD
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches and approvals
16.1.2.3.2 Deals
16.1.2.3.3 Expansions
16.1.2.4 MnM view
16.1.2.4.1 Right to win
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses and competitive threats
16.1.3 SIEMENS HEALTHINEERS AG
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches and approvals
16.1.3.3.2 Deals
16.1.3.3.3 Expansions
16.1.3.4 MnM view
16.1.3.4.1 Right to win
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses and competitive threats
16.1.4 QUIDELORTHO CORPORATION
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product launches and approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Right to win
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses and competitive threats
16.1.5 DANAHER
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches and approvals
16.1.5.3.2 Deals
16.1.5.3.3 Expansions
16.1.5.4 MnM view
16.1.5.4.1 Right to win
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses and competitive threats
16.1.6 WERFEN
16.1.6.1 Business overview
16.1.6.2 Products offered
16.1.6.3 Recent developments
16.1.6.3.1 Product launches and approvals
16.1.6.3.2 Deals
16.1.6.3.3 Expansions
16.1.6.4 MnM view
16.1.6.4.1 Right to win
16.1.6.4.2 Strategic choices
16.1.6.4.3 Weaknesses and competitive threats
16.1.7 BD
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product launches and approvals
16.1.7.3.2 Deals
16.1.7.3.3 Expansions
16.1.8 THERMO FISHER SCIENTIFIC INC.
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Deals
16.1.9 BIOM?RIEUX
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches and approvals
16.1.9.3.2 Deals
16.1.10 EKF DIAGNOSTICS HOLDINGS PLC
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches and approvals
16.1.10.3.2 Expansions
16.1.10.3.3 Other developments
16.1.11 TRINITY BIOTECH
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches and approvals
16.1.11.3.2 Deals
16.1.12 ORASURE TECHNOLOGIES, INC.
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches and approvals
16.1.12.3.2 Deals
16.1.13 GRIFOLS S.A.
16.1.13.1 Business overview
16.1.13.2 Products offered
16.1.13.3 Recent developments
16.1.13.3.1 Product launches and approvals
16.1.14 QIAGEN
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches and approvals
16.1.14.3.2 Deals
16.1.14.3.3 Expansions
16.2 OTHER PLAYERS
16.2.1 NOVA BIOMEDICAL
16.2.1.1 Business overview
16.2.1.2 Products offered
16.2.1.3 Recent developments
16.2.1.3.1 Product launches and approvals
16.2.1.3.2 Deals
16.2.2 SEKISUI DIAGNOSTICS
16.2.2.1 Business overview
16.2.2.2 Products offered
16.2.2.3 Recent developments
16.2.2.3.1 Product launches and approvals
16.2.3 SEKISUI DIAGNOSTICS
16.2.3.1 Business overview
16.2.3.2 Products offered
16.2.3.3 Recent developments
16.2.3.3.1 Product launches and approvals
16.2.4 LIFESCAN IP HOLDINGS, LLC
16.2.5 PTS DIAGNOSTICS
16.2.6 EUROLYSER DIAGNOSTICA GMBH
16.2.7 RESPONSE BIOMEDICAL
16.2.8 ALFA SCIENTIFIC DESIGNS, INC.
16.2.9 BTNX INC.
16.2.10 ASCENSIA DIABETES CARE HOLDINGS AG
16.2.11 FLUXERGY
16.2.12 PRECISION BIOSENSOR, INC.
16.2.13 ACON LABORATORIES, INC.
16.2.14 MENARINI DIAGNOSTICS S.R.L
16.2.15 MANKIND PHARMA
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.2 RESEARCH APPROACH
17.2.1 SECONDARY RESEARCH
17.2.1.1 Key data from secondary sources
17.2.2 PRIMARY DATA
17.2.2.1 Primary sources
17.2.2.2 Key data from primary sources
17.2.2.3 Key industry insights
17.3 MARKET SIZE ESTIMATION
17.3.1 BOTTOM-UP APPROACH
17.3.1.1 Approach 1: Company revenue estimation approach
17.3.1.2 Approach 2: Presentations of companies and primary interviews
17.3.1.3 Growth forecast
17.3.2 TOP-DOWN APPROACH
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION
17.5 MARKET SHARE ANALYSIS
17.6 RESEARCH ASSUMPTIONS
17.6.1 PARAMETRIC ASSUMPTIONS
17.6.2 GROWTH RATE ASSUMPTIONS
17.7 RESEARCH LIMITATIONS
17.8 RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2025 VS. 2035 VS. 2045
TABLE 2 GLOBAL DIABETES ESTIMATES (AGES 20–79) BY REGION, 2024 VS. 2030 VS. 2045 (IN THOUSANDS)
TABLE 3 PRODUCT WAIVERS, BY KEY PLAYER, 2021–2026
TABLE 4 POC DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2024–2031
TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 7 EUROPE: MACROECONOMIC INDICATORS
TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 11 POC DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 12 AVERAGE SELLING PRICE OF POC TESTS, BY PRODUCT, 2023–2025
TABLE 13 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2023–2025
TABLE 14 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2023–2025
TABLE 15 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2023–2025
TABLE 16 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2023–2025
TABLE 17 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 18 LIST OF MAJOR PATENTS PERTAINING TO POC DIAGNOSTICS MARKET, 2023–2025
TABLE 19 KEY COMPANIES IMPLEMENTING AI IN POC DIAGNOSTICS MARKET
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 GLOBAL STANDARDS IN POC DIAGNOSTICS MARKET
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
TABLE 27 KEY BUYING CRITERIA, BY TECHNOLOGY
TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 29 POC DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 30 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 31 KEY BIOCHEMISTRY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 32 POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 EUROPE: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 KEY IMMUNOASSAY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 38 POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 EUROPE: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 44 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 KEY RT-PCR-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 50 POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 KEY INAAT-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 56 POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
TABLE 62 KEY BLOOD SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 63 POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 EUROPE: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 69 POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 EUROPE: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 KEY URINE SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 75 POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 EUROPE: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 KEY OTHER SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 81 POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
TABLE 87 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 88 POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 EUROPE: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 94 POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 EUROPE: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 100 POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 106 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 EUROPE: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 111 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 EUROPE: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, B
Y COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 116 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 EUROPE: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 126 POC GLUCOSE MONITORING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128 NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
TABLE 133 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 ASIA PACIFIC: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 LATIN AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
TABLE 139 GLUCOSE MONITORING METERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 EUROPE: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 LATIN AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
TABLE 145 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 146 NORTH AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 EUROPE: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 ASIA PACIFIC: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 LATIN AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 KEY CARDIOMETABOLIC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 151 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 153 NORTH AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 EUROPE: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 ASIA PACIFIC: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 LATIN AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 158 NORTH AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 EUROPE: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 ASIA PACIFIC: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 LATIN AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 NORTH AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 EUROPE: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 ASIA PACIFIC: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 LATIN AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 HBA1C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 NORTH AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 EUROPE: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 ASIA PACIFIC: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 LATIN AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 173 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 185 INFLUENZA TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 ASIA PACIFIC: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 LATIN AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 191 TUBERCULOSIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 ASIA PACIFIC: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 LATIN AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 197 OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 ASIA PACIFIC: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 LATIN AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 KEY HAI TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 203 HAI TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 EUROPE: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 ASIA PACIFIC: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 LATIN AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 209 TROPICAL DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 210 NORTH AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 EUROPE: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 ASIA PACIFIC: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 LATIN AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 215 STD TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 EUROPE: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 LATIN AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 221 HIV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 222 NORTH AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 EUROPE: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 ASIA PACIFIC: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 LATIN AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227 HEPATITIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 228 NORTH AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229 EUROPE: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 ASIA PACIFIC: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 LATIN AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 233 HEPATITIS B TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 234 NORTH AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 EUROPE: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 ASIA PACIFIC: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 LATIN AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 239 HEPATITIS C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 240 NORTH AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 EUROPE: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 ASIA PACIFIC: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243 LATIN AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 245 SYPHILIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 246 NORTH AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 EUROPE: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 ASIA PACIFIC: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 LATIN AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 250 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 251 HPV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 252 NORTH AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 EUROPE: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 ASIA PACIFIC: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 LATIN AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 257 CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 258 NORTH AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 EUROPE: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 ASIA PACIFIC: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 1 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2025 VS. 2035 VS. 2045
TABLE 2 GLOBAL DIABETES ESTIMATES (AGES 20–79) BY REGION, 2024 VS. 2030 VS. 2045 (IN THOUSANDS)
TABLE 3 PRODUCT WAIVERS, BY KEY PLAYER, 2021–2026
TABLE 4 POC DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2024–2031
TABLE 6 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 7 EUROPE: MACROECONOMIC INDICATORS
TABLE 8 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 9 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 10 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 11 POC DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 12 AVERAGE SELLING PRICE OF POC TESTS, BY PRODUCT, 2023–2025
TABLE 13 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2023–2025
TABLE 14 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2023–2025
TABLE 15 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2023–2025
TABLE 16 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2023–2025
TABLE 17 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 18 LIST OF MAJOR PATENTS PERTAINING TO POC DIAGNOSTICS MARKET, 2023–2025
TABLE 19 KEY COMPANIES IMPLEMENTING AI IN POC DIAGNOSTICS MARKET
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 GLOBAL STANDARDS IN POC DIAGNOSTICS MARKET
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
TABLE 27 KEY BUYING CRITERIA, BY TECHNOLOGY
TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 29 POC DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 30 POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 31 KEY BIOCHEMISTRY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 32 POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 33 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 EUROPE: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37 KEY IMMUNOASSAY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 38 POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 39 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 EUROPE: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 44 POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 KEY RT-PCR-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 50 POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 KEY INAAT-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 56 POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2024–2031 (USD MILLION)
TABLE 57 NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58 EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
TABLE 62 KEY BLOOD SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 63 POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 64 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65 EUROPE: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 69 POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2024–2031 (USD MILLION)
TABLE 70 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 EUROPE: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 KEY URINE SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 75 POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 76 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 EUROPE: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 KEY OTHER SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 81 POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 82 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
TABLE 87 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 88 POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 89 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 EUROPE: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 94 POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 EUROPE: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 100 POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY REGION, 2024–2031 (USD MILLION)
TABLE 106 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 EUROPE: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 111 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 EUROPE: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, B
Y COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 116 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 EUROPE: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 121 NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 EUROPE: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 126 POC GLUCOSE MONITORING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128 NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
TABLE 133 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 134 NORTH AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 ASIA PACIFIC: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 LATIN AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
TABLE 139 GLUCOSE MONITORING METERS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 EUROPE: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 LATIN AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
TABLE 145 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 146 NORTH AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 EUROPE: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 ASIA PACIFIC: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 LATIN AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 KEY CARDIOMETABOLIC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 151 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152 POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 153 NORTH AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 EUROPE: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 ASIA PACIFIC: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 LATIN AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 158 NORTH AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 EUROPE: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 ASIA PACIFIC: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 LATIN AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 163 NORTH AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 EUROPE: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 ASIA PACIFIC: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 LATIN AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 HBA1C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 168 NORTH AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 EUROPE: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 ASIA PACIFIC: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 LATIN AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 173 POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179 RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 180 NORTH AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 EUROPE: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 ASIA PACIFIC: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 LATIN AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 185 INFLUENZA TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 NORTH AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EUROPE: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 ASIA PACIFIC: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 LATIN AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 191 TUBERCULOSIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 192 NORTH AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 EUROPE: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 ASIA PACIFIC: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 LATIN AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 197 OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 ASIA PACIFIC: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 LATIN AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 KEY HAI TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 203 HAI TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 EUROPE: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 ASIA PACIFIC: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 LATIN AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 209 TROPICAL DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 210 NORTH AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 EUROPE: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 ASIA PACIFIC: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 LATIN AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 215 STD TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 216 NORTH AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217 EUROPE: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 ASIA PACIFIC: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 LATIN AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 221 HIV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 222 NORTH AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 EUROPE: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 ASIA PACIFIC: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 LATIN AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227 HEPATITIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 228 NORTH AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 229 EUROPE: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 ASIA PACIFIC: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 LATIN AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 233 HEPATITIS B TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 234 NORTH AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 EUROPE: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 ASIA PACIFIC: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 LATIN AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 239 HEPATITIS C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 240 NORTH AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 EUROPE: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 ASIA PACIFIC: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243 LATIN AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 245 SYPHILIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 246 NORTH AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 EUROPE: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 ASIA PACIFIC: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 LATIN AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 250 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 251 HPV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 252 NORTH AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 EUROPE: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 ASIA PACIFIC: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 LATIN AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 257 CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 258 NORTH AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 EUROPE: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260 ASIA PACIFIC: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
Tumor/Cancer Markers Market
Tumor/cancer markers are substances produced by cancerous or other body cells in response to cancer or certain benign (non-cancerous) conditions. These markers help diagnose cancer and predict a patient’s response towards certain cancer therapies and treatment.This market accounted for XX% of the POC diagnostics kits market in 2013 and is expected to grow at a CAGR of XX% from 2013 to 2018, to reach $XX million by 2018.
Competitive Situation And Trends
New product launches is the key strategy adopted by industry players in order to achieve growth in the POC diagnostics market. This strategy accounted for a share of XX% of all growth strategies adopted by market players. The rising demand for POC devices as well as the high growth in emerging markets has encouraged companies to adopt this strategy. Market players are focusing on entering new markets by launching technologically advanced and innovative POC products, systems, and testing kits in both existing and emerging markets. Alere, Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Siemens Healthcare (Germany), Roche Diagnostics Limited (Switzerland), and Bayer Healthcare AG (Germany) are some of the leading market players that adopted this strategy in order to develop their business.
Key Growth Strategies, 2011–2014
